A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis
Latest Information Update: 10 Jul 2025
At a glance
- Drugs CSL 787 (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Sponsors CSL Behring
Most Recent Events
- 10 Jul 2025 New trial record